Literature DB >> 3905165

Interpretation of drug levels in acute and chronic disease states.

E Perucca, R Grimaldi, A Crema.   

Abstract

Serum drug concentration monitoring can be an invaluable aid to patient management, particularly in certain pathological conditions when individualisation of dosage is particularly critical. To be clinically useful, however, drug levels must be interpreted in the context of all factors that could influence the correlation between the concentration of the drug in plasma and the intensity of action. Several such factors may be operating in acute and chronic disease states. For example, a number of pathological conditions are associated with marked changes in the fraction of free, pharmacologically active drug in plasma and this will result in disruption of the normal relationship between total serum drug level and effect, as seen for phenytoin in uraemia. An altered response to a given serum drug level in disease states may also be caused by changes in tissue distribution, by abnormal accumulation of pharmacologically active metabolites in plasma or by changes in end-organ responsiveness. The latter are best illustrated by the altered sensitivity to digoxin in patients with various conditions, including hypokalaemia and thyroid disease. In addition to the factors listed above, consideration should also be given to potential interactions with concomitantly used drugs and to the possibility of analytical errors, especially in view of the evidence that the performance of otherwise reliable drug assays may be grossly impaired in certain diseases (e.g. uraemia), due to abnormal plasma composition and/or accumulation of interfering metabolites. In view of these complexities, a correct interpretation of serum drug levels requires a good knowledge of clinical pharmacology and a close collaboration between physician and laboratory. In any case, serum drug concentrations, like other laboratory tests, are not a substitute for careful patient observation, and any decision about drug treatment should be primarily based upon evaluation of the clinical state and, whenever possible, direct measurement of drug effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905165     DOI: 10.2165/00003088-198510060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  64 in total

1.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

2.  The use of digitalis in patients with pulmonary disease.

Authors:  L H Green; T W Smith
Journal:  Ann Intern Med       Date:  1977-10       Impact factor: 25.391

3.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

4.  Inhibition of binding of tritiated digoxin to myocardium by sodium depletion in dogs.

Authors:  C E Harrison; K G Wakim
Journal:  Circ Res       Date:  1969-02       Impact factor: 17.367

5.  Insensitivity to digoxin associated with hypocalcemia.

Authors:  D Chopra; P Janson; C T Sawin
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

6.  An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls.

Authors:  H W Clague; Y Twum-Barima; S G Carruthers
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

7.  Abnormal theophylline levels in plasma by fluorescence polarization immunoassay in patients with renal disease.

Authors:  J A Patel; L T Clayton; C P LeBel; K D McClatchey
Journal:  Ther Drug Monit       Date:  1984       Impact factor: 3.681

Review 8.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 9.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

10.  Interpretation of serum phenytoin concentrations in uremia is assay-dependent.

Authors:  M A Sirgo; P J Green; M L Rocci; P H Vlasses
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

View more
  7 in total

Review 1.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 2.  Is there a role for therapeutic drug monitoring of new anticonvulsants?

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 3.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.

Authors:  A Baruzzi; M Contin; E Perucca; F Albani; R Riva
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 7.  Alfentanil infusions in patients requiring intensive care.

Authors:  A Bodenham; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.